| Products and compositions |
2022-10-04 |
2022-11-18 |
|
| Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell |
2022-9-01 |
2023-3-09 |
|
| Nucleic acids for inhibiting expression of pros1 in a cell |
2022-7-25 |
2023-1-19 |
|
| Nucleic acids for inhibiting expression of c3 in a cell |
2022-5-26 |
2023-1-26 |
|
| Sirna targeting tmprss6 for the treawtment of myeloproliferative disorders |
2022-4-26 |
2022-11-03 |
|
| Nucleic acids for inhibiting expression of xdh in a cell |
2022-4-19 |
2022-10-27 |
|
| Nucleic acids for inhibiting expression of lpa in a cell |
2022-3-17 |
2022-9-15 |
|
| Products and compositions |
2022-3-07 |
2022-9-15 |
|
| Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene … |
2022-3-03 |
2022-9-09 |
|
| Nucleic acids for inhibiting expression of lpa in a cell |
2021-12-22 |
2022-6-02 |
|
| Nucleic acids for inhibiting expression of pros1 in a cell |
2021-11-02 |
2022-10-01 |
|
| Products and compositions |
2021-10-05 |
2022-1-27 |
|
| Nucleic acids for inhibiting expression of cnnm4 in a cell |
2021-5-26 |
2021-12-02 |
|
| Nucleic acid linked to a trivalent glycoconjugate |
2020-11-25 |
2021-3-18 |
|
| Interfering rna molecules |
2020-8-07 |
2021-3-04 |
|
| Nucleic acids for inhibiting expression of a target gene comprising … |
2020-5-12 |
2020-6-30 |
|
| Nucleic acids for inhibiting expression of pros1 in a cell |
2020-5-06 |
2020-11-12 |
|
| Nucleic acids for inhibiting expression of c3 in a cell |
2019-11-22 |
2022-1-20 |
|
| Nucleic acids for inhibiting expression of LPA in a cell |
2019-11-13 |
2023-1-31 |
|
| nucleic acids to inhibit the expression of tmprss6 and iron chelators |
2019-7-26 |
2021-4-27 |
|
| Nucleic acids for inhibiting expression of c3 in a cell |
2019-4-26 |
2020-10-28 |
|
| Sirnas with vinylphosphonate at the 5' end of the antisense strand |
2019-4-05 |
2021-2-17 |
|
| Sirnas with at least two ligands at different ends |
2019-4-05 |
2021-2-17 |
|
| Nucleic acids for inhibiting expression of lpa in a cell |
2018-11-13 |
2023-2-13 |
|
| Nucleic acids for inhibiting expression of aldh2 in a cell |
2018-11-13 |
2019-5-16 |
|
| Nucleic acid conjugates |
2018-9-28 |
2018-11-14 |
|
| Products and compositions |
2018-9-28 |
2019-10-09 |
|
| Products and compositions |
2018-7-05 |
2018-8-22 |
|
| Nucleic acid conjugates |
2018-7-05 |
2018-8-22 |
|
| Products and compositions |
2018-6-21 |
2019-5-15 |
|
| FATS, FAT COMPLEXES AND USE ABOUT THESE |
2018-5-03 |
2018-12-12 |
|
| Products and compositions |
2018-4-05 |
2022-12-13 |
|
| Nucleic acid conjugates |
2018-4-05 |
2019-10-09 |
|
| Products and compositions for inhibiting expression of a target gene |
2018-4-05 |
2019-10-09 |
|
| Ligand modified double-stranded nucleic acids |
2018-4-05 |
2018-10-11 |
|
| Further novel oligonucleotide-ligand conjugates |
2018-4-05 |
2022-4-12 |
2022-4-12 |
| Products and compositions |
2018-4-05 |
2023-1-23 |
|
| Nucleic acid conjugates |
2018-4-05 |
2018-10-11 |
|
| gemcitabine derivatives for cancer therapy |
2018-3-19 |
2019-12-13 |
|
| Means for lung specific delivery |
2018-2-14 |
2019-2-07 |
|
| Phosphorodithioate linkages |
2018-1-16 |
2018-2-28 |
|
| Further novel forms of interfering rna molecules |
2018-1-14 |
2018-2-01 |
|
| Bulge constructs |
2017-5-25 |
2017-7-12 |
|
| Modified positions |
2017-5-25 |
2017-7-12 |
|
| Double targeting |
2017-5-25 |
2017-7-12 |
|
| RXi with gainac targeting ligand |
2017-5-05 |
2017-6-21 |
|
| Bulge constructs |
2017-5-05 |
2017-6-21 |
|
| Double targeting |
2017-5-05 |
2017-6-21 |
|
| Modified positions |
2017-5-05 |
2017-6-21 |
|
| Products and compositions |
2017-4-05 |
2018-10-10 |
|
| Products and compositions |
2017-4-05 |
2018-10-10 |
|
| Lipoplex formulations for specific delivery to vascular endothelium |
2017-3-30 |
2017-10-19 |
|
| Lipid nanoparticle formulation |
2016-10-31 |
2018-5-02 |
|
| Modified guide rnas, methods and uses |
2016-10-24 |
2017-4-27 |
|
| Lipid complexes coated with peg and their uses |
2016-9-07 |
2017-7-07 |
|
| Means for inhibiting the expression of protein kinase 3 |
2016-4-08 |
2016-5-05 |
|
| Sirna tp801 inhibitors for use in combination with vegf inhibitors or vegf- … |
2016-1-18 |
2018-11-29 |
|
| Means for inhibiting the expression of edn1 |
2015-11-30 |
2016-6-02 |
|
| Means for the treatment of pre-eclampsia |
2015-11-30 |
2016-6-02 |
|
| Means for inhibiting the expression of protein kinase |
2015-9-17 |
2016-3-11 |
|
| Use of vegfr1 as a biomarker |
2015-8-28 |
2015-12-24 |
|
| Further use of protein kinase n beta |
2015-7-13 |
2015-11-26 |
|
| Means for inhibiting the expression of ang2 |
2014-5-29 |
2014-11-06 |
|
| Means for inhibiting the expression of orc-1 |
2014-5-12 |
2014-9-04 |
|
| Means for inhibiting the expression of protein kinase 3 |
2014-3-20 |
2014-4-10 |
|
| Means for inhibiting the expression of protein kinase 3 |
2014-3-20 |
2016-5-12 |
2016-5-12 |
| Lipoplex formulations for specific delivery to vascular endothelium |
2013-11-11 |
2013-11-28 |
|
| Use of protein kinase n beta |
2013-9-18 |
2013-10-10 |
|
| Further novel forms of interfering RNA molecules |
2012-8-22 |
2016-1-14 |
2016-1-14 |
| Therapeutic uses of inhibitors of RTP801 |
2011-9-15 |
2015-6-16 |
2015-6-16 |
| Combinations of TGF-beta and Cox-2 inhibitors and methods for their therapeutic … |
2011-5-04 |
2013-3-20 |
|
| Composition and methods of rnai therapeutics for treatment of cancer and other … |
2011-1-13 |
2011-5-26 |
|
| New factor involved in metastasis and use thereof |
2010-12-22 |
2011-6-30 |
|
| Rare earth-doped up-conversion nanoparticles for therapeutic and diagnostic … |
2010-11-22 |
2012-11-14 |
|
| Means for inhibiting the expression of opa1 |
2010-2-12 |
2010-11-25 |
|
| Targets for tumor growth inhibition |
2009-12-29 |
2010-8-12 |
|
| Compositions comprising cmyc sirna and methods of use thereof |
2009-6-11 |
2011-8-04 |
|
| Composition and method of RNAi therapeutics for treatment of cancer and other … |
2009-4-09 |
2010-8-31 |
2010-8-31 |
| Compositions comprising notch1 sirna and methods of use thereof |
2009-3-12 |
2011-5-05 |
|
| Compositions comprising nuclear factor-kappa b (nf-kb) sirna and methods of use |
2009-3-12 |
2011-3-03 |
|
| Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of … |
2009-3-09 |
2011-3-17 |
|
| Compositions comprising survivin sirna and methods of use thereof |
2009-3-09 |
2011-3-03 |
|
| Heterobifunctional polyethylene glycol reagents |
2008-11-12 |
2011-11-17 |
|
| Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo |
2008-10-10 |
2009-4-23 |
|
| Compositions comprising k-ras sirna and methods of use |
2008-9-18 |
2009-9-03 |
|
| Compositions comprising hif-1 alpha sirna and methods of use thereof |
2008-9-18 |
2010-11-04 |
|
| Compositions comprising stat5 sirna and methods of use thereof |
2008-9-17 |
2010-10-28 |
|
| Compositions comprising stat3 sirna and methods of use thereof |
2008-9-17 |
2010-6-02 |
|
| Compositions comprising human integrin-linked kinase-sirna and methods of use … |
2008-9-04 |
2010-11-04 |
|
| Methods and compositions for treatment of cancer and other angiogenesis-related … |
2008-7-03 |
2011-1-20 |
|
| Compositions comprising human EGFR-SIrna and methods of use |
2008-6-20 |
2010-8-11 |
|
| Means for inhibiting the expression of protein kinase 3 |
2007-7-20 |
2014-7-09 |
|
| Means for inhibiting the expression of cd31 |
2007-4-20 |
2008-12-31 |
|
| Therapeutic uses of inhibitors of RTP801 |
2007-1-18 |
2009-2-25 |
|
| Sirna compositions promoting scar-free wound healing of skin and methods for … |
2006-12-29 |
2007-7-12 |
|
| Inhibitory polynucleotide compositions and methods for treating cancer |
2006-12-21 |
2011-2-17 |
|
| COMPOSITIONS AND METHODS OF USING siRNA TO KNOCKDOWN GENE EXPRESSION AND TO … |
2006-11-30 |
2008-9-03 |
|
| Therapeutic methods for nucleic acid delivery vehicles |
2006-11-02 |
2007-9-20 |
|
| Immunotherapeutic agent |
2005-11-22 |
2009-8-04 |
2009-8-04 |
| Compositions for treating respiratory viral infections and their use |
2005-11-04 |
2012-8-01 |
|